Table 2. Clinical characteristics and administered therapies according to the molecular profiling of the first 19 patients.
| Patient ID | Age [years] | ECOG PS | Cancer Type | No. of cycles before ONCO-T-PROFILE | Experimental Regimen | PFS vs. ePFS [days] | PFS Ratio > 1.3 |
|---|---|---|---|---|---|---|---|
| P1 | 44 | 2 | CRC | 8 | nab-Paclitaxel + Gemcitabine* | 86 vs. 56 | No |
| P2 | 65 | 0 | CRC | 7 | Doxorubicin* | 98 vs. 62 | No |
| P4 | 68 | 0 | Sarcoma, NOS | 4 | Paclitaxel + Gemcitabine | 44 vs. 237 | Yes |
| P3 | 47 | 2 | Adrenocortical Carcinoma | 5 | nab-Paclitaxel* | 56 vs. 30 | No |
| P15 | 37 | 1 | Breast Cancer | 8 | Exemestane + Everolimus | 184 vs. 249 | Yes |
| P5 | 67 | 1 | Liposarcoma | 5 | Gemcitabine | 269 vs. 93 | No |
| P18 | 64 | 0 | Breast Cancer | 5 | Carboplatin + Gemcitabine | 220 vs. 250 | No |
| P7 | 46 | 2 | Pancreatic Cancer | 2 | Regorafenib* | 36 vs. 56 | No |
| P8 | 55 | 2 | SCLC | 5 | Irinotecan* | 54 vs. 68 | No |
| P9 | 67 | 1 | NET | 2 | Topotecan | 89 vs. 194 | Yes |
| P11 | 69 | 0 | NSCLC | 4 | Gemcitabine | 62 vs. 135 | Yes |
| P6 | 83 | 0 | Endometrial Carcinoma | 2 | Liposomal Doxorubicin | 243 vs. 74 | No |
| P12 | 49 | 1 | Gastric Cancer | 3 | Epirubicin + Docetaxel | 204 vs. 100 | No |
| P10 | 51 | 0 | Breast Cancer | 2 | Exemestane + Everolimus | 17 vs. 124 | Yes |
| P16 | 64 | 1 | Endometrial Carcinoma | 2 | Liposomal Doxorubicin | 71 vs. 156 | Yes |
| P14 | 45 | 0 | Breast Cancer | 3 | Exemestane + Everolimus | 242 vs. 325 | Yes |
| P17 | 25 | 0 | Ovarian Cancer | 1 | Everolimus | 83 vs. 156 | Yes |
| P19 | 67 | 2 | CCC | 5 | nab-Paclitaxel* | 264 vs. 57 | No |
| P13 | 57 | 1 | CRC | 3 | Regorafenib | 223 vs. 176 | No |
Abbreviations: CRC: colorectal cancer, NOS: not otherwise specified, SCLC: small cell lung cancer, NSCLC: non-small cell lung cancer, NET: neuroendocrine tumor, CCC: cholangiocellular-carcinoma.
*
therapies which are not used in the respective indication